BRPI0924137A2 - composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade - Google Patents

composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade

Info

Publication number: BRPI0924137A2
Authority: BR; Brazil
Prior art keywords: losartan; amlodipine; pharmaceutical composition; solid pharmaceutical; better stability
Prior art date: 2009-01-23

Application number

BRPI0924137A

Other languages

English (en)

Inventor

Taek Yim Ho

Hyun Park Jae

Hyun Im Ji

Soo Kim Kyeong

Original Assignee

Hanmi Holdings Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-23

Filing date

2009-06-05

Publication date

2019-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924137(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-05 Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd

2019-09-24 Publication of BRPI0924137A2 publication Critical patent/BRPI0924137A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BRPI0924137A 2009-01-23 2009-06-05 composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade BRPI0924137A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20090005840		2009-01-23
KR1020090036011A KR101232296B1 (ko)	2009-01-23	2009-04-24	안정성이 향상된 암로디핀 및 로자탄을 함유하는 고형 약제학적 조성물
PCT/KR2009/003028 WO2010085027A1 (en)	2009-01-23	2009-06-05	Solid pharmaceutical composition comprising amlodipine and losartan with improved stability

Publications (1)

Publication Number	Publication Date
BRPI0924137A2 true BRPI0924137A2 (pt)	2019-09-24

Family

ID=42306870

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0924136A BRPI0924136B8 (pt)	2009-01-23	2009-02-13	composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BRPI0924137A BRPI0924137A2 (pt)	2009-01-23	2009-06-05	composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
BRPI0924135A BRPI0924135A2 (pt)	2009-01-23	2009-12-28	composição farmacêutica sólida compreendendo anlodipino e losartan

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0924136A BRPI0924136B8 (pt)	2009-01-23	2009-02-13	composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BRPI0924135A BRPI0924135A2 (pt)	2009-01-23	2009-12-28	composição farmacêutica sólida compreendendo anlodipino e losartan

Country Status (32)

Country	Link
US (3)	US9161933B2 (pt)
EP (3)	EP2413931B1 (pt)
JP (3)	JP5658172B2 (pt)
KR (2)	KR101232296B1 (pt)
CN (4)	CN102292085B (pt)
AR (3)	AR070897A1 (pt)
AU (3)	AU2009338267B2 (pt)
BR (3)	BRPI0924136B8 (pt)
CA (3)	CA2749903C (pt)
CL (1)	CL2011001781A1 (pt)
CO (3)	CO6361914A2 (pt)
CR (3)	CR20110449A (pt)
DO (3)	DOP2011000229A (pt)
EA (3)	EA020103B1 (pt)
EC (1)	ECSP11011253A (pt)
ES (3)	ES2580777T3 (pt)
HN (2)	HN2011002020A (pt)
IL (3)	IL214146A0 (pt)
JO (2)	JO3328B1 (pt)
MA (3)	MA33056B1 (pt)
MX (3)	MX349221B (pt)
MY (3)	MY173823A (pt)
NI (3)	NI201100143A (pt)
NZ (3)	NZ594738A (pt)
PE (4)	PE20140978A1 (pt)
SA (1)	SA110310070B1 (pt)
SG (3)	SG173044A1 (pt)
TW (3)	TWI404534B (pt)
UA (3)	UA102721C2 (pt)
UY (2)	UY32388A (pt)
WO (3)	WO2010085014A1 (pt)
ZA (3)	ZA201106162B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG173044A1 (en)	2009-01-23	2011-08-29	Hanmi Holdings Co Ltd	Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
JP6106359B2 (ja) *	2010-12-13	2017-03-29	第一三共ヘルスケア株式会社	ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) *	2011-09-13	2016-12-14	大日本住友製薬株式会社	イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101861307B1 (ko) *	2011-10-13	2018-07-06	한미약품 주식회사	정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) *	2011-12-30	2018-12-11	한미약품 주식회사	로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) *	2012-04-11	2014-10-08	兆科药业（合肥）有限公司	一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) *	2012-04-17	2014-05-07	한국유나이티드제약 주식회사	안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) *	2012-06-07	2017-07-12	大正製薬株式会社	ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) *	2013-09-24	2015-03-26	대봉엘에스 주식회사	직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
KR20150056443A (ko) *	2013-11-15	2015-05-26	한미약품 주식회사	타다라필 및 암로디핀을 포함하는 복합제제
WO2015072700A1 (en) *	2013-11-15	2015-05-21	Hanmi Pharm. Co., Ltd.	Composite formulation comprising tadalafil and amlodipine
KR101910901B1 (ko) *	2013-11-29	2018-10-24	한미약품 주식회사	암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) *	2014-09-30	2022-03-03	한미약품 주식회사	암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) *	2015-01-22	2015-05-13	华东理工常熟研究院有限公司	氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko)	2015-03-31	2018-11-05	한미약품 주식회사	암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
MX382254B (es) *	2015-06-30	2025-03-13	Hanmi Pharmaceutical Co Ltd	Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
KR101750689B1 (ko) *	2015-09-15	2017-06-26	주식회사 종근당	약제학적 복합제제
CN119523985A (zh) *	2017-05-27	2025-02-28	青岛海蓝医药有限公司	川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN107260735A (zh) *	2017-07-25	2017-10-20	合肥华方医药科技有限公司	生物利用度提高的二氢吡啶类药物组合物
CN107308158A (zh) *	2017-07-28	2017-11-03	合肥华方医药科技有限公司	一种提高非洛地平生物利用度的药物组合物
CN107308159A (zh) *	2017-07-28	2017-11-03	合肥华方医药科技有限公司	一种提高伊拉地平生物利用度药物组合物
JP7166754B2 (ja) *	2017-11-22	2022-11-08	沢井製薬株式会社	ダサチニブ無水物含有製剤
CN108542891A (zh) *	2018-06-07	2018-09-18	董贵雨	一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) *	2018-12-07	2020-06-11	ニプロ株式会社	アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) *	2019-06-25	2021-03-30	경남과학기술대학교 산학협력단	라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR102900997B1 (ko)	2019-12-11	2025-12-22	한미약품 주식회사	암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
CN115666564B (zh)	2020-06-09	2024-07-16	韩美药品株式会社	在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
CN112274490B (zh) *	2020-11-19	2022-11-22	四川尚锐生物医药有限公司	一种氨氯地平氯沙坦钾复方组合物的制备方法
WO2025224756A1 (en) *	2024-04-23	2025-10-30	Mestastop Solutions Private Limited	Composition, method and use thereof for delaying primary tumor metastasis using amlodipine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
US5138069A (en)	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
AU685898B2 (en)	1993-12-23	1998-01-29	Du Pont Merck Pharmaceutical Company, The	Polymorphs of losartan and the process for the preparation of form II of losartan
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
JP2003507418A (ja) *	1999-08-24	2003-02-25	メディキュアインターナショナルインコーポレイテッド	心血管疾患とその関連疾患の治療
US20020068740A1 (en) *	1999-12-07	2002-06-06	Mylari Banavara L.	Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
AU2001279284A1 (en) *	2000-07-05	2002-01-14	Capricorn Pharma, Inc	Rapid-melt semi-solid compositions, methods of making same and methods of using same
CA2420844A1 (en) *	2000-08-30	2003-02-28	Sankyo Company, Limited	Medicinal compositions for preventing or treating heart failure
AT5874U1 (de)	2000-12-29	2003-01-27	Bioorg Bv	Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) *	2001-03-29	2004-10-12	한미약품 주식회사	신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2003035046A2 (en)	2001-10-18	2003-05-01	Novartis Ag	Salts formed of an at1-receptor antagonist and a cardiovascular agent
HUP0501067A2 (en)	2001-11-14	2006-02-28	Teva Pharma	Amorphous and crystalline forms of losartan potassium and process for their preparation
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
US7157100B2 (en)	2002-06-04	2007-01-02	J.B. Chemicals & Pharmaceuticals Ltd.	Pharmaceutical composition for controlled drug delivery system
WO2004067512A1 (en)	2003-01-27	2004-08-12	Hanmi Pharm. Co., Ltd.	Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
EP1648357A2 (en) *	2003-07-18	2006-04-26	Pneu Medex Inc.	Fluid operated actuators and pneumatic unloading orthoses
SI1653950T1 (sl)	2003-07-31	2008-06-30	Nicox Sa	Nitrooksi derivati losartana, valsatana, kandesartana, telmisartana, eprosartana in olmesartana kotblokatorji receptorja angiotenzina-II za zdravljenje kardiovaskularnih bolezni
WO2005070462A2 (en)	2004-01-12	2005-08-04	Sepracor, Inc.	Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
EA013053B1 (ru) *	2004-11-05	2010-02-26	Бёрингер Ингельхайм Интернациональ Гмбх	Двуслойная таблетка, содержащая телмисартан и амлодипин
KR100582347B1 (ko) *	2004-12-30	2006-05-22	한미약품 주식회사	3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
JP5063370B2 (ja)	2005-06-27	2012-10-31	第一三共株式会社	湿式造粒製薬の調製方法
TWI388345B (zh) *	2005-06-27	2013-03-11	Sankyo Co	用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
AU2006307470A1 (en) *	2005-10-27	2007-05-03	Lupin Limited	Pharmaceutical formulation of losartan
US20080261958A1 (en)	2005-11-08	2008-10-23	Randy Lee Webb	Combination of Organic Compounds
JP5179363B2 (ja) *	2005-12-22	2013-04-10	武田薬品工業株式会社	固形製剤
KR100742432B1 (ko) *	2005-12-27	2007-07-24	한미약품 주식회사	암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko)	2006-07-21	2009-08-26	한미약품 주식회사	(ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en)	2006-08-11	2008-02-28	Shinobu Nagahama	Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023958A1 (en)	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en)	2006-08-24	2008-10-02	Hanall Pharmaceutical Co., Ltd.	Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en)	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) *	2006-10-10	2009-03-11	한올제약주식회사	시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko)	2006-12-08	2013-03-26	한미사이언스 주식회사	암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
SG173044A1 (en)	2009-01-23	2011-08-29	Hanmi Holdings Co Ltd	Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same

2009
- 2009-02-13 SG SG2011052081A patent/SG173044A1/en unknown
- 2009-02-13 ES ES09838901.8T patent/ES2580777T3/es active Active
- 2009-02-13 EP EP09838901.8A patent/EP2413931B1/en not_active Not-in-force
- 2009-02-13 CA CA2749903A patent/CA2749903C/en not_active Expired - Fee Related
- 2009-02-13 MX MX2011006009A patent/MX349221B/es active IP Right Grant
- 2009-02-13 NZ NZ594738A patent/NZ594738A/xx not_active IP Right Cessation
- 2009-02-13 UA UAA201110285A patent/UA102721C2/uk unknown
- 2009-02-13 AU AU2009338267A patent/AU2009338267B2/en not_active Ceased
- 2009-02-13 JP JP2011547742A patent/JP5658172B2/ja not_active Expired - Fee Related
- 2009-02-13 MY MYPI2011003307A patent/MY173823A/en unknown
- 2009-02-13 WO PCT/KR2009/000704 patent/WO2010085014A1/en not_active Ceased
- 2009-02-13 BR BRPI0924136A patent/BRPI0924136B8/pt not_active IP Right Cessation
- 2009-02-13 EA EA201170958A patent/EA020103B1/ru not_active IP Right Cessation
- 2009-02-13 MA MA34109A patent/MA33056B1/fr unknown
- 2009-02-13 CN CN200980155068.4A patent/CN102292085B/zh active Active
- 2009-02-13 US US13/139,673 patent/US9161933B2/en active Active
- 2009-03-13 AR ARP090100916A patent/AR070897A1/es not_active Application Discontinuation
- 2009-04-24 KR KR1020090036011A patent/KR101232296B1/ko active Active
- 2009-05-14 PE PE2014000392A patent/PE20140978A1/es not_active Application Discontinuation
- 2009-05-14 PE PE2009000681A patent/PE20100559A1/es not_active Application Discontinuation
- 2009-06-05 CA CA2749955A patent/CA2749955C/en not_active Expired - Fee Related
- 2009-06-05 AU AU2009338280A patent/AU2009338280B2/en not_active Ceased
- 2009-06-05 JP JP2011547746A patent/JP5660544B2/ja not_active Expired - Fee Related
- 2009-06-05 ES ES09838914.1T patent/ES2505116T3/es active Active
- 2009-06-05 CN CN2009801550699A patent/CN102292070A/zh active Pending
- 2009-06-05 EA EA201170959A patent/EA021763B1/ru not_active IP Right Cessation
- 2009-06-05 WO PCT/KR2009/003028 patent/WO2010085027A1/en not_active Ceased
- 2009-06-05 MY MYPI20113306 patent/MY151550A/en unknown
- 2009-06-05 EP EP09838914.1A patent/EP2391348B1/en not_active Not-in-force
- 2009-06-05 MX MX2011006061A patent/MX345868B/es active IP Right Grant
- 2009-06-05 BR BRPI0924137A patent/BRPI0924137A2/pt not_active IP Right Cessation
- 2009-06-05 UA UAA201110284A patent/UA102720C2/ru unknown
- 2009-06-05 NZ NZ594740A patent/NZ594740A/xx not_active IP Right Cessation
- 2009-06-05 SG SG2011052107A patent/SG173046A1/en unknown
- 2009-06-05 US US13/139,426 patent/US8673944B2/en not_active Expired - Fee Related
- 2009-06-05 CN CN201610294905.3A patent/CN105998017A/zh active Pending
- 2009-06-05 MA MA34111A patent/MA33058B1/fr unknown
- 2009-06-18 TW TW098120461A patent/TWI404534B/zh not_active IP Right Cessation
- 2009-09-24 KR KR1020090090540A patent/KR101160151B1/ko active Active
- 2009-12-28 EA EA201170960A patent/EA019471B1/ru not_active IP Right Cessation
- 2009-12-28 MA MA34110A patent/MA33057B1/fr unknown
- 2009-12-28 ES ES09838934.9T patent/ES2526606T3/es active Active
- 2009-12-28 AU AU2009338251A patent/AU2009338251B2/en not_active Ceased
- 2009-12-28 UA UAA201110283A patent/UA105203C2/ru unknown
- 2009-12-28 CA CA2749957A patent/CA2749957C/en not_active Expired - Fee Related
- 2009-12-28 JP JP2011547763A patent/JP5466716B2/ja not_active Expired - Fee Related
- 2009-12-28 BR BRPI0924135A patent/BRPI0924135A2/pt not_active IP Right Cessation
- 2009-12-28 WO PCT/KR2009/007829 patent/WO2010085047A2/en not_active Ceased
- 2009-12-28 EP EP09838934.9A patent/EP2391365B1/en not_active Not-in-force
- 2009-12-28 NZ NZ594739A patent/NZ594739A/xx not_active IP Right Cessation
- 2009-12-28 US US13/140,348 patent/US8673945B2/en not_active Expired - Fee Related
- 2009-12-28 MY MYPI20113305 patent/MY150974A/en unknown
- 2009-12-28 CN CN200980155067.XA patent/CN102292084B/zh not_active Expired - Fee Related
- 2009-12-28 SG SG2011052099A patent/SG173045A1/en unknown
- 2009-12-28 PE PE2011001358A patent/PE20120428A1/es active IP Right Grant
- 2009-12-28 MX MX2011006008A patent/MX345956B/es active IP Right Grant
2010
- 2010-01-19 AR ARP100100112A patent/AR075028A1/es not_active Application Discontinuation
- 2010-01-19 AR ARP100100111A patent/AR075027A1/es not_active Application Discontinuation
- 2010-01-20 SA SA110310070A patent/SA110310070B1/ar unknown
- 2010-01-21 JO JOP/2010/0015A patent/JO3328B1/ar active
- 2010-01-21 JO JOP/2010/0014A patent/JO2981B1/ar active
- 2010-01-22 UY UY0001032388A patent/UY32388A/es not_active Application Discontinuation
- 2010-01-22 TW TW099101765D patent/TW201031404A/zh unknown
- 2010-01-22 TW TW099101765A patent/TWI395583B/zh not_active IP Right Cessation
- 2010-01-22 UY UY0001032389A patent/UY32389A/es not_active Application Discontinuation
- 2010-01-22 PE PE2010000052A patent/PE20100739A1/es not_active Application Discontinuation
2011
- 2011-07-18 DO DO2011000229A patent/DOP2011000229A/es unknown
- 2011-07-18 IL IL214146A patent/IL214146A0/en not_active IP Right Cessation
- 2011-07-18 IL IL214147A patent/IL214147A/en active IP Right Grant
- 2011-07-18 DO DO2011000231A patent/DOP2011000231A/es unknown
- 2011-07-18 DO DO2011000230A patent/DOP2011000230A/es unknown
- 2011-07-18 IL IL214145A patent/IL214145A0/en not_active IP Right Cessation
- 2011-07-21 HN HN2011002020A patent/HN2011002020A/es unknown
- 2011-07-21 HN HN2011002022A patent/HN2011002022A/es unknown
- 2011-07-22 CL CL2011001781A patent/CL2011001781A1/es unknown
- 2011-07-22 NI NI201100143A patent/NI201100143A/es unknown
- 2011-07-22 NI NI201100144A patent/NI201100144A/es unknown
- 2011-07-22 NI NI201100145A patent/NI201100145A/es unknown
- 2011-08-09 EC EC2011011253A patent/ECSP11011253A/es unknown
- 2011-08-19 CO CO11105490A patent/CO6361914A2/es not_active Application Discontinuation
- 2011-08-19 CO CO11105492A patent/CO6361915A2/es not_active Application Discontinuation
- 2011-08-19 CO CO11105496A patent/CO6361905A2/es not_active Application Discontinuation
- 2011-08-22 CR CR20110449A patent/CR20110449A/es unknown
- 2011-08-22 ZA ZA2011/06162A patent/ZA201106162B/en unknown
- 2011-08-22 ZA ZA2011/06161A patent/ZA201106161B/en unknown
- 2011-08-22 CR CR20110450A patent/CR20110450A/es unknown
- 2011-08-22 ZA ZA2011/06160A patent/ZA201106160B/en unknown
- 2011-08-22 CR CR20110448A patent/CR20110448A/es unknown

Also Published As

Publication number	Publication date
TWI395583B (zh)	2013-05-11
CN102292084B (zh)	2014-01-29
EP2413931A4 (en)	2012-08-08
IL214145A0 (en)	2011-08-31
CO6361915A2 (es)	2012-01-20
CN102292085B (zh)	2017-01-18
SA110310070B1 (ar)	2014-09-02
DOP2011000229A (es)	2011-10-15
MX2011006008A (es)	2011-06-28
CO6361905A2 (es)	2012-01-20
BRPI0924136A8 (pt)	2017-10-03
CN105998017A (zh)	2016-10-12
EP2413931A1 (en)	2012-02-08
US20110245301A1 (en)	2011-10-06
US8673944B2 (en)	2014-03-18
KR101160151B1 (ko)	2012-06-27
JP5658172B2 (ja)	2015-01-21
UA102720C2 (ru)	2013-08-12
UY32389A (es)	2010-02-26
TWI404534B (zh)	2013-08-11
BRPI0924136B8 (pt)	2021-05-25
CA2749955C (en)	2016-07-26
EP2391348A4 (en)	2012-07-25
NI201100144A (es)	2012-11-06
CA2749955A1 (en)	2010-07-29
MY151550A (en)	2014-06-13
UA102721C2 (uk)	2013-08-12
KR20100086913A (ko)	2010-08-02
NZ594739A (en)	2013-11-29
DOP2011000231A (es)	2011-10-15
CA2749957A1 (en)	2010-07-29
EA201170958A1 (ru)	2012-01-30
ZA201106160B (en)	2012-10-31
MX345868B (es)	2017-02-21
US9161933B2 (en)	2015-10-20
CN102292070A (zh)	2011-12-21
HN2011002022A (es)	2014-02-03
EP2391365B1 (en)	2014-11-26
CA2749957C (en)	2016-07-26
CN102292084A (zh)	2011-12-21
MX2011006009A (es)	2011-06-28
DOP2011000230A (es)	2011-10-15
ES2505116T3 (es)	2014-10-09
UY32388A (es)	2010-02-26
US20110251245A1 (en)	2011-10-13
PE20140978A1 (es)	2014-08-16
IL214147A0 (en)	2011-08-31
BRPI0924136B1 (pt)	2019-10-15
KR101232296B1 (ko)	2013-02-13
ES2580777T8 (es)	2016-09-22
AU2009338267A2 (en)	2011-09-29
EA020103B1 (ru)	2014-08-29
EA201170959A1 (ru)	2011-12-30
SG173046A1 (en)	2011-08-29
MX349221B (es)	2017-07-19
HK1163539A1 (en)	2012-09-14
TW201031404A (en)	2010-09-01
TW201028151A (en)	2010-08-01
MY173823A (en)	2020-02-24
US20110245302A1 (en)	2011-10-06
MA33056B1 (fr)	2012-02-01
EP2413931B1 (en)	2016-06-01
BRPI0924135A2 (pt)	2016-02-10
WO2010085027A1 (en)	2010-07-29
PE20100739A1 (es)	2010-11-19
CO6361914A2 (es)	2012-01-20
CR20110450A (es)	2011-11-10
AU2009338251B2 (en)	2014-03-13
NZ594738A (en)	2013-11-29
EA021763B1 (ru)	2015-08-31
MA33057B1 (fr)	2012-02-01
NI201100145A (es)	2012-08-17
CR20110448A (es)	2011-11-10
NZ594740A (en)	2013-11-29
ES2580777T3 (es)	2016-08-26
JP2012515767A (ja)	2012-07-12
ZA201106162B (en)	2012-10-31
EP2391365A2 (en)	2011-12-07
US8673945B2 (en)	2014-03-18
NI201100143A (es)	2012-08-17
EA019471B1 (ru)	2014-03-31
MY150974A (en)	2014-03-31
ES2526606T3 (es)	2015-01-13
JP5466716B2 (ja)	2014-04-09
AU2009338267B2 (en)	2014-09-18
JO3328B1 (ar)	2019-03-13
HN2011002020A (es)	2014-02-03
AR075028A1 (es)	2011-03-02
EP2391348B1 (en)	2014-08-27
AU2009338280B2 (en)	2014-05-01
BRPI0924136A2 (pt)	2017-06-13
JO2981B1 (ar)	2016-09-05
CR20110449A (es)	2011-11-10
JP5660544B2 (ja)	2015-01-28
WO2010085047A3 (en)	2010-11-04
EP2391348A1 (en)	2011-12-07
EA201170960A1 (ru)	2012-01-30
MX2011006061A (es)	2011-06-24
JP2012515770A (ja)	2012-07-12
MX345956B (es)	2017-02-28
IL214147A (en)	2016-08-31
PE20100559A1 (es)	2010-09-12
ZA201106161B (en)	2012-10-31
WO2010085014A1 (en)	2010-07-29
AU2009338280A1 (en)	2011-09-15
UA105203C2 (ru)	2014-04-25
EP2391365A4 (en)	2012-07-25
PE20120428A1 (es)	2012-05-17
AU2009338251A1 (en)	2011-09-15
AR075027A1 (es)	2011-03-02
MA33058B1 (fr)	2012-02-01
JP2012515768A (ja)	2012-07-12
CL2011001781A1 (es)	2012-03-23
ECSP11011253A (es)	2011-09-30
SG173044A1 (en)	2011-08-29
SG173045A1 (en)	2011-08-29
AR070897A1 (es)	2010-05-12
AU2009338267A1 (en)	2011-09-15
CA2749903C (en)	2016-09-06
IL214146A0 (en)	2011-08-31
KR20100086921A (ko)	2010-08-02
CA2749903A1 (en)	2010-07-29
WO2010085047A2 (en)	2010-07-29
CN102292085A (zh)	2011-12-21

Publication	Publication Date	Title
BRPI0924137A2 (pt)	2019-09-24	composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
BRPI0920521A2 (pt)	2018-01-16	combinação farmacêutica
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
BRPI0906962A2 (pt)	2015-07-14	Composto, e, composição farmacêutica
BRPI0906556A2 (pt)	2015-07-07	Composto, e, composição farmacêutica
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
EP2451274A4 (en)	2014-04-02	Pharmaceutical compositions
DK3492069T3 (da)	2022-03-14	Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2285357T3 (da)	2014-06-02	Farmaceutisk sammensætning omfattende brivaracetam
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
BRPI1009372A2 (pt)	2016-05-31	compostos, composição farmacêutica e respectivos usos
SMT201400005B (it)	2014-03-07	Composto anticancro e composizione farmaceutica che l contiene
BRPI0917681A2 (pt)	2015-08-04	Composto, e, composição farmacêutica
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
DK2391349T3 (da)	2014-11-03	Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
PL2379086T3 (pl)	2016-01-29	Preparat farmeceutyczny
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
DK2391351T3 (da)	2014-12-01	Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BR112012000831A2 (pt)	2019-09-24	compostos, composições farmacêuticas e métodos relacionados

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2019-12-10	B25F	Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement	Owner name: HANMI HOLDINGS CO., LTD (KR) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME E DE SEDE REQUERIDAS ATRAVES DA PETICAO NO 860150179905, DE 17/08/2015, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2020-03-31	B25E	Requested change of name of applicant rejected	Owner name: HANMI HOLDINGS CO., LTD (KR) Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO 860150179905 DE 17/08/2015 EM VIRTUDE DOS DESPACHOS PUBLICADOS NAS RPI?S NO 2553 DE 10/12/2019 E 2559 DE 21/01/2020.